I am a
Home I AM A Search Login

Papers of the Week

2020 Apr

CNS Spectr



172 A Phase 3, Multicenter Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Olanzapine/Samidorphan in Patients with Schizophrenia.


Yagoda S, Graham C, Simmons A, Arevalo C, Cheng Y, McDonnell D
CNS Spectr. 2020 Apr; 25(2):309-310.
PMID: 32331006.


Background: ALKS 3831, a combination of olanzapine and samidorphan (OLZ/SAM), is in development for the treatment of schizophrenia and is intended to provide the antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain. We report the safety, tolerability, and efficacy of OLZ/SAM in patients with schizophrenia in a phase 3, 52-week, open-label extension study.